MAGEA3 and non-small cell lung carcinoma: Apart from this, other adenovirus vaccines expressing melanoma-associated antigen 3 (MAGE-A3) and MG1 maraba oncolytic virus (MG1-MAGEA3) were tested in phase I/II dose-escalation trial (NCT02879760) testing the combinatorial efficacy of the vaccine with Pembrolizumab, is presently recruiting NSCLC patients who have shown signs of radiological progression with at least one cycle of platinum-doublet chemotherapy [69].